Schoenebaum noted "the company’s CFO yesterday explicitly said that 1Q consensus sales estimates need to come down. Previously, the company had commented that 1Q sales would be sequentially below 4Q sales – but the company appears to be saying that the decline could be far more significant than the Street is currently estimating."
Dendreon has indicated that it expects Provenge to return to positive growth after Q1, at which stage a direct-to-consumer advertising campaign is expected to begin. Schoenebaum’s comments appeared to reflect a broadly held view, however, when he noted that limited visibility on future performance and a competitive impact that will only intensify moving forward had driven his move away from a 'buy' rating
Life is back at DNDN and with EU collaboration DNDN will remain as wallstreet darling in coming days.
These presentations at AUA provide the medical community with possible new insight on the role of PROVENGE in men with advanced prostate cancer
DNDN need not to worry about Zytiga or Xtandi competitions.
PROVENGE research presented at this year's AUA Annual Meeting reflects Dendreon's ongoing commitment to men in need of new treatment options for advanced prostate cancer," said Mark Frohlich, M.D.,
Think !!! are they stupid to say "PROVENGE is an innovative treatment option that uses a patient's own cells to activate the immune system to fight the disease, and these data reinforce what we have seen in the clinical setting."
• Abstract #960: E. David Crawford, M.D., professor of surgery, urology, and radiation oncology, and head of the section of urologic oncology at the University of Colorado Denver School of Medicine, will present a poster titled "Optimal Timing for Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): Sequencing and Identifying Parameters of Early Progression with Sipuleucel-T:" In the Phase 3 IMPACT trial, a retrospective subgroup analysis suggested a greater PROVENGE treatment effect in those patients with a lower baseline PSA. These data were recently published in the international journal, Urology.
• Abstract #971: Thomas Gardner, M.D., associate professor in the Department of Microbiology and Immunology at Indiana University School of Medicine, will present a poster titled "Safety and Changes in Laboratory Parameters Associated with Sipuleucel-T in Patients with Metastatic Castration-Resistant Prostate Cancer: Phase II ProACT study:" A Phase II study evaluated immune responses and overall survival of patients receiving PROVENGE manufactured with different concentrations of antigen. Increased globulin protein and transient increased eosinophil counts were consistent with previous studies and positively correlated with immune response and overall survival. The safety profile of PROVENGE was consistent with that observed in previous clinical trials.
• Abstract #972: Matthew Cooperberg, M.D., assistant professor of urology, epidemiology and biostatistics, University of California, San Francisco, will present a poster titled "Treatment Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Prior to Receiving Sipuleucel-T: Data from PROCEED:" In a Phase IV registry study, data on patients enrolled before they received PROVENGE provides a window into current treatment patterns for patients with advanced prostate cancer and will continue to yield important information that can be used to track trends in patient demographics and treatment prior to and after receiving PROVENGE.
"These presentations at AUA provide the medical community with possible new insight on the role of PROVENGE in men with advanced prostate cancer," said E. David Crawford, M.D., professor of surgery, urology, and radiation oncology, and head of the section of urologic oncology at the University of Colorado, Denver School of Medicine